Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Lenalidomide + Dexamethasone in Newly Diagnosed t(11;14) Multiple Myeloma
NCT03785184Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants Who Achieve Complete Response at 24 months. Planned start Apr 2019; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03785184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785184.